A study to confirm the superiority of celecoxib 100 mg BID to loxoprofen 60 mg TID in the
incidence of gastroduodenal endoscopic ulcers after 2 weeks treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.